RAYDIAX, a spin-off of the STIMULATE research campus/Otto-von-Guericke-University Magdeburg, has secured €7.5 million for first-in-human studies and the market entry of its therapy assistance CT “TACT.”
The round includes €5 million in venture capital from existing business angels, current investor bmp Ventures with the IBG funds, as well as a new investment from the GETEC Family Office of Dr. Karl Gerhold.
Related: CrannMed secures €12.5M in EIC funds for new pain relief device
In addition, the company has been awarded €2.5 million from the European Commission’s EIC Accelerator program – one of the most prestigious funding instruments for deep-tech innovation in Europe.
With the newly raised capital, RAYDIAX will implement the first-in-human application of its therapy assistance CT scanner “TACT” to generate early clinical evidence. In parallel, the company will advance development toward series maturity and expand its organizational structures in sales, production, and quality management. The goal is to systematically prepare for the first commercial installations.
Dr. Thomas Hoffmann, CEO and Co-Founder of RAYDIAX: “With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application. Following the successful seed phase and the development of our preclinical prototype, we are now focusing on generating early clinical evidence as part of the planned first-in-human studies.
At the same time, we are establishing the organizational foundations for market entry. The continued trust of our existing investors, along with the support of new strategic partners, confirms the technological maturity and market potential of our approach.”
The clinical phase now commencing marks a significant value-creation step in the development of the system and lays the foundation for regulatory approval and commercial scaling.
With TACT, RAYDIAX is developing a dedicated therapy assistance CT scanner for minimally invasive cancer treatments. The system supports therapy planning, execution, and monitoring within an integrated platform specifically optimized for interventional applications.
Minimally invasive therapies are gaining increasing importance in light of an aging population and rising cancer incidence. In many cases, they enable a less invasive treatment compared to open surgical procedures, potentially shorten procedure and hospital stay times, and help reduce complication rates. This can create additional treatment capacity and relieve pressure on hospital structures.
With the market launch of the TACT system, RAYDIAX aims to significantly expand the range of applications for minimally invasive cancer therapies.
The support from the European Union through the EIC Accelerator program underscores the strategic importance of the technology at the European level. The funding program specifically supports companies with disruptive innovations and high scaling potential.
Steffen Schmidt, CFO of the GETEC Group: “As the GETEC Group, we are pleased to invest in innovative technologies at our locations. After investing in new technological approaches in the field of magnetic resonance imaging through Neoscan Solutions, we became aware of RAYDIAX in the CT sector. With its innovative technology, RAYDIAX enables focused live CT
imaging that reduces radiation exposure for both patients and physicians, as well as procedure time in the operating room. In addition to increasing efficiency in medical processes, RAYDIAX has also made a larger CT gantry opening possible, which will enable new surgical methods in the future, such as the use of robotics. Altogether, this convinced us.”
Klemens Gutmann, Founder of Regiocom and Business Angel: “As an engineer, I am particularly interested in complex technical systems. The strong scientific foundation and the outstanding technical expertise of the founding team convinced me. The TACT system fills a functional gap in operating room workflows – specifically in interventional radiology.”
Dr. Jan Alberti, Managing Partner at bmp Ventures: “With the successful closing of the Series A1, RAYDIAX reaches a decisive turning point from technology development to clinical application and market entry. TACT addresses a clearly defined clinical need in interventional oncology and has the potential to establish a new device category for minimally invasive cancer therapies. We see RAYDIAX as being exceptionally well positioned to establish an international presence in this growing market segment.”
Dr. Jan Engels, Senior Investment Manager at High-Tech Gründerfonds: “RAYDIAX is developing a technology with the potential to significantly improve the care of cancer patients. We are proud to see the strong progress the team has made since our seed investment – culminating in the recently closed Series A1 and the prestigious EIC Accelerator grant. Since the early stages, Thomas and his team have consistently taken the right steps toward achieving clinical relevance, and we look forward to continuing to support them closely on their journey.”
RAYDIAX is a spin-off of the Magdeburg-based STIMULATE research campus. This internationally renowned research center for minimally invasive image-guided therapies provides an ideal environment for device and company development.
Prof. Dr. rer. nat. Georg Rose, Chairman of the Board of the STIMULATE Research Campus: “The EIC Accelerator is one of the most selective funding programs for deep-tech innovation in Europe. That RAYDIAX has successfully passed this highly competitive process and closed its Series A1 financing round is an outstanding achievement. It confirms the scientific excellence, the technological and clinical differentiation of the TACT system, as well as the entrepreneurial maturity of the team. For the STIMULATE Research Campus at Otto von Guericke University Magdeburg, this sends a strong signal: long-term medical technology research conducted here is giving rise to internationally competitive high-tech companies with clinical and economic relevance.”
